Biotech Newswire – Frequently Asked Questions (FAQ)
What makes Biotech Newswire different from generic PR distribution services?
Why is the global press release distribution important in biotech?
How does Biotech Newswire ensure better visibility than generic newswires?
What kind of distribution options do you offer?
Does the Standard package include a Post-Release Report?
What channels are included in the distribution?
How do I write AI-optimized press releases?
Why is a well-structured press release so important?
How does Biotech Newswire help with AI optimization?
What are the benefits of AI optimization?
What does your Post-Release Report include?
Why are typical monitoring reports from newswires misleading?
Is Biotech Newswire affordable for biotech SMEs?
Who typically uses Biotech Newswire?
What types of announcements work best with Biotech Newswire?
Does the Biotech Newswire serve public companies?
How quickly can you distribute my press release?
Can Biotech Newswire help with content creation?
Do I need a PR agency to reach trade media?
Do I need a PR agency for media relations?
Why do PR agencies often push generic newswires?
What is the pricing?
How can I get started?
What makes Biotech Newswire different from generic PR distribution services?
Generic newswires (Business Wire, PR Newswires, GlobeNewswire, Access Newswire, etc.) distribute your press release mostly to irrelevant media, TV and radio stations and daily newspapers. Typically, only 20% or less are biotech-specific.
Biotech Newswire is 100% specialized in biotech, pharma, life science, and medtech trade media ensuring your news reaches editors, investors, and partners who actually matter.
Why is the global press release distribution important in biotech?
Many trade media have an international readership and biotech audiences are global by nature. Limiting your distribution to one region, such as the U.S. or Europe, means missing up to half of the relevant biotech and pharma trade outlets and therefore much less visibility to the audience you need to reach.
Many companies choose regional distribution because global options through general newswires are very expensive. That’s where Biotech Newswire makes a difference. We specialize exclusively in biotech, pharma, and medtech trade media, with a database that reaches approximately 40% U.S., 40% European, and 20% Rest-of-World outlets. This targeted expertise allows us to deliver a global distribution at a fraction of the usual cost, making worldwide visibility both effective and affordable.
For our clients the global distribution means maximum visibility for funding news, clinical updates, drug discovery and research news, new products and services etc.
How does Biotech Newswire ensure better visibility than generic newswires?
We combine:
- A curated and targeted media list refined over 25+ years
- Distribution through many targeted vertical channels (e.g. Clinical Trials, Oncology, Biomanufacturing, Lab & Research etc.)
- Unmatched social media visibility (250,000+ biotech professionals through X and LinkedIn)
- AI-optimized press releases (MeSH tagging + ChatGPT enhancement)
- Global outreach
This multi-layered approach gives your press release maximum industry visibility. In contrast, generic newswire only distribute press releases to key biotech and healthcare media but lack the targeted vertical channels, social media visibility and AI enhancement.
What kind of distribution options do you offer?
We offer two distribution options:
- Standard Media distribution: This option provides broad, worldwide visibility for companies that need an efficient media push within the biotech and life sciences sector.
- Enhanced Media distribution: Includes all media contacts from the Standard Distribution, however, we’ll add:
- Targeted vertical channels
- Targeted social media outreach (reaches 250,000+ biotech/pharma professionals)
- AI optimization of the press release
Post-Release Report: Both distribution options receive a detailed engagement report, including trade media interactions, social media reach, and performance metrics, giving you clear insights into the effectiveness of your press release distribution.
Does the Standard package include a Post-Release Report?
Yes.
What channels are included in the distribution?
We currently have 30 targeted vertical channels and micro channels. We add as many channels as fit to the topic of the press release.
How do I write AI-optimized press releases?
As more people use AI search engines to discover information, PR professionals need a new approach to writing effective news releases. Focus on clear, structured content that answers key questions (who, what, when, where, why) and includes authoritative data. Use relevant keywords naturally, avoid keyword stuffing, and ensure the format is easy for AI systems to parse and understand.
Structure for Clarity
- Use a descriptive headline that includes primary keywords.
- Start with a bullet-point summary to highlight key information.
- Answer the 5 W’s and H (who, what, when, where, why, how) in the opening paragraph.
Enhance Readability
- Keep paragraphs short and focused on one idea.
- Use subheadings to break up content and improve scannability.
- Incorporate bullet points for lists and important details.
Why is a well-structured press release so important?
AI cares about structured, clear, semantically rich content. Adding the right keywords in the right position is about adding structure, enhancing the semantic clarity of the text itself and improving machine readability and search discoverability for greater impact.
How does Biotech Newswire help with AI optimization?
We recognized the growing importance of artificial intelligence in news discovery in 2020 and have since routinely enriched press releases with MeSH terms, the same controlled vocabulary used by PubMed to index scientific publications. In 2023, we added AIO and ChatGPT-powered semantic analysis to further optimize each press release for AI systems.
What are the benefits of AI optimization?
AI is transforming how investors, big pharma and media discover and manage news. AI optimization helps your press release appear in
- Investor screening workflows (VCs scanning deal flow using AI tools)
- Partnering and M&A scouting tools
- Business intelligence and industry databases that rely on machine-readable content
- AI-powered CMS in editorial departments that facilitate news sifting and research
What does your Post-Release Report include?
The Post-Release Report provides transparent, meaningful insights, including:
- Media open stats
- Engagement metrics
- Listing of trade media that opened your press release
- Social media visibility
- LinkedIn groups where your news appeared
All data is GDPR-compliant and focuses on real trade media engagement.
Why are typical monitoring reports from newswires misleading?
The monitoring reports from generic newswires rely on automated syndication, not editorial interest. Syndication guarantees placements of press releases on partner websites which means:
- No editorial review
- No real engagement
- Inflated “pickup” numbers
In contrast, Biotech Newswire tracks actual editorial openings and engagements by biotech and pharma media.
Is Biotech Newswire affordable for biotech SMEs?
Yes, affordability is one of our core advantages.
We offer:
- Fee-for-service pricing (no long-term contracts)
- Global distribution at regional prices
- No word count limits
Who typically uses Biotech Newswire?
Our clients include:
- Biotech and pharma SMEs
- Publicly listed biotech and pharma companies
- CROs, CMOs, CDMOs
- Diagnostics and medtech companies
- Research institutions
- Life science vendors and service providers
- PR agencies
What types of announcements work best with Biotech Newswire?
Biotech Newswire is ideal for announcements such as:
- Drug discovery & research news
- Clinical trial updates
- Licensing deals
- Funding announcements
- CMO/CDMO news
- Product & service launches
- Executive and board appointments
If in doubt please ask us.
Does the Biotech Newswire serve public companies?
Yes, we have many public companies as clients. Being a specialist newswire we do not comply with the regulatory aspects of the stock markets. We advise listed companies to book a general newswire like PR Newswire or Access Newswire to meet the compliance requirements. and to use the Biotech Newswire to reach the trade media worldwide. This way the customer has the best cost/benefit ratio.
How quickly can you distribute my press release?
The best is to send us the final version of the press release as a Word document (incl. logo and picture/visual, if applicable) the day prior to the planned distribution latest and specify at what time you want to have it distributed. In urgent cases, we’ll be able to distribute on short notice (turnaround time 2 to 4 hours). Please note that we are located in the EST time zone.
Can Biotech Newswire help with content creation?
No. We do not offer content creation services.
Do I need a PR agency to reach trade media?
No. Many biotech SMEs assume a PR agency is needed to secure trade media visibility. For routine biotech news a specialized distribution service is usually more effective and faster than a PR agency and far more cost-efficient. PR agencies add value when you need narrative building, feature stories or crisis communication.
Do I need a PR agency for media relations?
No. Most biotech SMEs have not yet drug products on the market. The goal of media relations is to maximize positive coverage in the media without paying for it directly through advertising. Media relations is especially important for big pharma.
Why do PR agencies often push generic newswires?
Some PR agencies receive kickbacks, free credits, or reseller discounts from major wire services. This can lead to biased recommendations.
What is the pricing?
Please contact us for pricing.
How can I get started?
Simply contact us when you plan a press release.